

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	Release of Security Interest		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Bank of America, N.A.		05/31/2007	National Association:
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Alliant Pharmaceuticals, Inc.		
<b>Street Address:</b>	312 Maxwell Road, Suite 400		
<b>City:</b>	Alpharetta		
<b>State/Country:</b>	GEORGIA		
<b>Postal Code:</b>	30004		
<b>Entity Type:</b>	CORPORATION:		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	76650092	ALLIANT PHARMACEUTICALS	
<b>Serial Number:</b>	72287396	RONDEC	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	(858)720-2555		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
<b>Phone:</b>	858-720-2500		
<b>Email:</b>	prosecutiondocketing@paulhastings.com		
<b>Correspondent Name:</b>	Jane Inyoung Song		
<b>Address Line 1:</b>	3579 Valley Centre Drive		
<b>Address Line 4:</b>	San Diego, CALIFORNIA 92130		
<b>ATTORNEY DOCKET NUMBER:</b>	59656.00047		
<b>NAME OF SUBMITTER:</b>	Jane Inyoung Song		
<b>Signature:</b>	/Jane Inyoung Song/		
<b>Date:</b>	06/21/2007		

CH \$65.00 76650092

**Total Attachments: 4**

source=release of security interest#page1.tif

source=release of security interest#page2.tif

source=release of security interest#page3.tif

source=release of security interest#page4.tif


**RELEASE OF SECURITY INTEREST  
IN UNITED STATES TRADEMARK**

FOR GOOD AND VALUABLE CONSIDERATION, receipt and sufficiency of which is hereby acknowledged, Bank of America, N.A., (the "Releasor"), hereby releases and terminates its security interest and lien in the United States trademarks owned by Alliant Pharmaceuticals, Inc. (the "Releasee") (the "Trademarks"), including without limitation the trademarks set forth on Schedule I attached hereto, further including without limitation any and all right, title and interest in and to the following, whether now existing or hereafter acquired: (i) trademarks, trade names, registered trademarks, trademark applications, service marks, registered service marks and service mark applications, including, without limitation, the trademarks, trade names, registered trademarks, trademark applications, service marks, registered service marks and service mark applications listed on Schedule I attached hereto and made a part hereof, and (a) all renewals thereof, (b) all income royalties, damages and payments now and hereafter due and/or payable under and with respect thereto, including, without limitation, payments under all licenses entered into in connection therewith and damages and payments for past or future infringements and dilutions thereof, (c) the right to sue or otherwise recover for past, present and future infringements and dilutions thereof, (d) the goodwill of Releasee's business symbolized by the foregoing and connected therewith, (e) all of Releasee's rights corresponding thereto throughout the world, and (f) all other proceeds and products of the foregoing, including (without limitation) any rights pursuant to its agreements with any other party relating thereto (all the foregoing trademarks, trade names, registered trademarks and trademark applications, service marks, registered service marks and service mark applications, together with the items described in clauses (a)-(f) above, are referred to herein as "the Trademarks"), and (ii) the goodwill of Releasee's business connected with and symbolized by the Trademarks.

THIS RELEASE is made in consideration of the satisfactory performance and payment of certain obligations pursuant to the Security Agreement by the Releasee.

IN WITNESS WHEREOF, the undersigned have executed this Release as of the 31st day of May, 2007.

BANK OF AMERICA, N.A.,  
as Releasor

By:   
Name: Tabra Lindsay  
Title: Senior Vice President

ALLIANT PHARMACEUTICALS, INC.,  
as Releasee

By: Mark Pugh  
Name: Mark Pugh  
Title: President

**SCHEDULE I**

**TRADEMARK**

<b><u>TRADEMARK/TRADENAME</u></b>	<b><u>SERIAL NO.</u></b>	<b><u>REG. NO./</u></b>
Alliant Pharmaceuticals	76/650,092	-
Rondec	72/287,396	0,854,529

CHI99 4833558-1.079853.0011